PHARMA MAR, S.A. «12345...» Página 2 de 11 desde 01/07/1988 hasta 24/05/2018 28/02/2018 17:55 PHARMA MAR, S.A. Corporate governance annual report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2017 Número de registro: 262348 28/02/2018 17:52 PHARMA MAR, S.A. Information on P&L The Company sends release regarding year 2017 results. Número de registro: 262346 28/02/2018 17:41 PHARMA MAR, S.A. Interim financial information La sociedad remite información sobre los resultados del segundo semestre de 2017 Número de registro: 262335 14/02/2018 08:15 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Pharma Mar licenses fully synthetic marine derived payloads to Seattle Genetics for use in drug conjugates. Número de registro: 261551 18/01/2018 19:00 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks CORAIL Phase III with Zepsire in resistant ovarian cancer has not met its primary endpoint. Número de registro: 260786 11/01/2018 17:58 PHARMA MAR, S.A. Liquidity contracts and specialists The Company reports details of the operations of the Liquidity Agreement between 11/10/2017 and 10/01/2018 Número de registro: 260607 09/01/2018 14:13 PHARMA MAR, S.A. Strategic plans, profit forecasts and presentations New corporate presentation (English version) which will be available in the Company´s web site. Número de registro: 260513 03/01/2018 09:24 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to the Significant Fact n. 259611, PharmaMar has requested from the European Medicines Agency the re-examination of the negative Opinion issued by the CHMP for Aplidin® for the indication of relapsed and refractory multiple myeloma. Número de registro: 260272 15/12/2017 12:43 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to the Significant Fact n. 258359, the CHMP of EMA has finally emitted its opinion against the approval of Aplidin® in multiple myeloma. Número de registro: 259611 11/12/2017 08:18 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to Significant Fact n 236.798, presentation of results from ADMYRE Phase III trial of plitidepsin in multiple myeloma at the 59th American Society of Hematology annual Meeting & Exposition. Número de registro: 259246 Página 2 de 11 «12345...»